139 related articles for article (PubMed ID: 6816610)
1. Platelets from diabetic subjects show diminished sensitivity to prostacyclin.
Betteridge DJ; El Tahir KE; Reckless JP; Williams KI
Eur J Clin Invest; 1982 Oct; 12(5):395-8. PubMed ID: 6816610
[TBL] [Abstract][Full Text] [Related]
2. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
[TBL] [Abstract][Full Text] [Related]
3. Platelet sensitivity to prostacyclin in diabetes mellitus.
Pillay PK; Pillay U; Balasubramaniam P; Lee KO
Ann Acad Med Singap; 1985 Apr; 14(2):229-31. PubMed ID: 3898978
[TBL] [Abstract][Full Text] [Related]
4. Refractoriness of diabetic platelets to inhibitory prostaglandins.
Lagarde M; Berciaud P; Burtin M; Dechavanne M
Prostaglandins Med; 1981 Oct; 7(4):341-7. PubMed ID: 6273957
[TBL] [Abstract][Full Text] [Related]
5. Platelet sensitivity to prostacyclin in pregnancy and uterine cancer.
Briel RC; Lippert TH
Eur J Obstet Gynecol Reprod Biol; 1981 Jun; 12(1):19-23. PubMed ID: 7018952
[TBL] [Abstract][Full Text] [Related]
6. Vascular prostacyclin, platelet sensitivity to prostaglandins and platelet-specific proteins in diabetes mellitus. Analysis of type of diabetes, state of metabolic control and diabetic microangiopathy.
Schernthaner G; Sinzinger H; Silberbauer K; Freyler H; Mühlhauser I; Kaliman J
Horm Metab Res Suppl; 1981; 11():33-43. PubMed ID: 6459282
[No Abstract] [Full Text] [Related]
7. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
[TBL] [Abstract][Full Text] [Related]
8. Platelet sensitivity in vitro to adenosine-5'-diphosphate and prostacyclin and diabetic retinopathy.
Davis TM; Bown E; Turner RC
Diabetologia; 1985 May; 28(5):274-6. PubMed ID: 3894139
[TBL] [Abstract][Full Text] [Related]
9. Increased platelet malondialdehyde, but normal platelet sensitivity to adenosine-5-diphosphate and prostacyclin in well-controlled type 1 diabetics without vascular complications.
Gisinger C; Schernthaner G
Diabetes Res; 1986 Oct; 3(8):401-5. PubMed ID: 3545622
[TBL] [Abstract][Full Text] [Related]
10. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
Hawiger J; Parkinson S; Timmons S
Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
[TBL] [Abstract][Full Text] [Related]
11. Altered platelet function in diabetes mellitus.
Colwell JA; Halushka PV; Sarji K; Levine J; Sagel J; Nair RM
Diabetes; 1976; 25(2 SUPPL):826-31. PubMed ID: 823064
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
Oyekan AO; Botting JH
Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
[TBL] [Abstract][Full Text] [Related]
13. [Platelet sensitivity to prostacyclin in diabetic and nondiabetic patients with atherosclerotic vascular changes: a measure of platelet membrane prostacyclin receptors?].
Klein K; Kaliman J; Sinzinger H; Silberbauer K
Vasa; 1980; 9(2):123-6. PubMed ID: 6256984
[No Abstract] [Full Text] [Related]
14. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.
Szczeklik A; Gryglewski RJ; Nizankowski R; Musiał J; Pietoń R; Mruk J
Pharmacol Res Commun; 1978 Jun; 10(6):545-56. PubMed ID: 358212
[No Abstract] [Full Text] [Related]
15. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic pregnancies.
Gerö G; Rákóczi I; Tihanyi K; Oláh J; Demeter J; Gáti I
Haemostasis; 1985; 15(6):377-83. PubMed ID: 3908235
[TBL] [Abstract][Full Text] [Related]
16. Heparin neutralization of PGI2: effects upon platelets.
Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
Eggerman TL; Harker LA; Andersen NH; Wilson CH
Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
[No Abstract] [Full Text] [Related]
18. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
[TBL] [Abstract][Full Text] [Related]
19. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
Siess W; Roth P; Weber PC
Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin analogs: antiaggregatory potency and enhancement of cAMP levels in human platelet rich plasma.
Dembinska-Kiec A; Rücker W; Schönhöfer PS; Gandolfi C
Thromb Haemost; 1979 Dec; 42(4):1340-3. PubMed ID: 232318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
